Identification of microRNAs that might be therapeutic target of malignant lymphomas
| Project/Area Number |
25461405
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Akita University |
|---|
Principal Investigator |
Tagawa Hiroyuki 秋田大学, 医学(系)研究科(研究院), 講師 (30373492)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
Tagawa Hiroyuki 秋田大学, 大学院医学系研究科, 講師 (30373492)
Takahashi Naoto 秋田大学, 大学院医学系研究科, 教授 (80344753)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Keywords | miRNA / malignant lymphoma / CTCL / Side population / miR-16 / miR-150 / CCR6 / metastasis / 悪性リンパ腫 / 転移浸潤 / ケモカインレセプターCCR6 / 皮膚浸潤性T細胞リンパ腫 / Bmi-1 / SP細胞 / マントル細胞リンパ腫 / SAHA / リンパ腫 / side population |
|---|
| Outline of Final Research Achievements |
In this study we scheduled following two purposes. (1) To identify specific miRNAs that may be associated with invasion and metastasis of CTCL, and (2) to Identify of specific miRNAs that is specifically regulated in side population of mantle cell lymphoma.
(1). In the presence of continuous CCR6 upregulation accompanied by miR-150 downregulation, IL-22 activation leads to continuous CCL20-CCR6 interaction in CTCL cells and, in turn, autocrine metastasis to distal organs Ito et al., 2014 Blood; Ikeda et al., 2016 Oncotarget).
(2). We found that Bmi-1 was over expressed in side population (SP) cells of relapsed MCL, ant its up regulation by miR-16 was deeply associated with MCL tumorigenesis via enhancing anti-apoptotic function (Teshima et al., 2014 Oncogene).
|
Report
(4 results)
Research Products
(30 results)
-
-
-
[Journal Article] Analysis of clinical characteristics and prognostic factors for angioimmunoblastic T-cell lymphoma.2015
Author(s)
Kameoka Y, Takahashi N, Itou S, Kume M, Noji H, Kato Y, Ichikawa Y, Sasaki O, Motegi M, Ishiguro A, Tagawa H, Ishizawa K, Ishida Y, Ichinohasama R, Harigae H, Sawada K.
-
Journal Title
Int J Hematol
Volume: 101
Issue: 6
Pages: 536-542
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Down-regulated expression of miR-155, miR-17, and miR-181b, and up-regulated expression of activation-induced cytidine deaminase and interferon-α in PBMCs from patients with SLE.2015
Author(s)
Kaga H, Komatsuda A, Omokawa A, Ito M, Teshima K, Tagawa H, Sawada K, Wakui H.
-
Journal Title
Mod Rheumatol.
Volume: 16
Issue: 6
Pages: 1-25
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
[Journal Article] MicroRNA-150 inhibits tumor invasion and metastasis by targeting the chemokine receptor, CCR6 in advanced cutaneous T-cell lymphoma2014
Author(s)
Ito M, Teshima K, Ikeda S, Kitadate A, Watanabe A, Nara M, Yamashita J, Ohshima K, Sawada K, Tagawa H
-
Journal Title
Blood
Volume: 123
Pages: 1499-1511
Related Report
Peer Reviewed
-
-
-
-
[Journal Article] Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells2013
Author(s)
Nara M, Teshima K, Watanabe A, Ito M, Iwamoto K, Kitabayashi A, Kume M, Hatano Y, Takahashi N, Iida S, Sawada K, Tagawa H
-
Journal Title
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
[Presentation] Silencing progression of tumor suppressive microRNAs essentially contributes to develop aggressive T-cell lymphoma.2015
Author(s)
Akihiro Kitadate, Mitsugu Ito, Sho Ikeda, Kazuaki Teshima, Naoko Hasunuma, Tomomitsu Miyagaki, Sugaya Makoto, Naoto Takahashi, Atsushi Komatuda , Hiroyuki Tagawa
Organizer
20th Congress of the European Hematology Association. (Abstract #E1361)
Place of Presentation
Vienna, Austla
Year and Date
2015-06-11
Related Report
-
-
-
-
-
-
-
-
-
-
-
